On December 21, Samsung Biologics announced that its portfolio company, Samsung Biologics America (SBA), will acquire a 100% stake in Human Genome Sciences from GSK. Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, the purchase price is $280 million.
Human Genome Sciences operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax.
Samsung Biologics is a leading contract development and manufacturing organization, offering end-to-end integrated services that range from late discovery to commercial manufacturing. SBA is Samsung Biologics’ American division.
This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.
According to data in the LevinPro HC database, this transaction represents the 49th Pharmaceuticals acquisition of the year. There were 66 Pharmaceuticals deals in 2024.
